BOSTON, Sept. 12, 2019 -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that it convened and then adjourned, without conducting any.

Histogenics Corporation (HSGX) (the “Company” or “Histogenics”) today announced that it intends to convene and then adjourn, without conducting any business, its special meeting of stockholders (the “Special Meeting”) to be held with respect to its proposed merger with Ocugen, Inc. (“Ocugen”) pursuant to the Agreement and Plan of Merger and Reorganization, dated as of April 5, 2019, as amended (the “Merger Agreement”), by and among the Company, its wholly-owned subsidiary, Restore Merger Sub, Inc. (“Merger Sub”) and Ocugen, which provides for the merger (the “Merger”) of Merger Sub with and into Ocugen. The Special Meeting is being adjourned in order to solicit additional proxies for the proposals to be presented at the Special Meeting.

Entera Bio Ltd. (ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as its U.S.-based CFO. Mr. Lieber will be responsible for all investor relations, finance and administrative functions, and will lead the Company’s future financing efforts to support the company’s growth initiatives.

Q4 2019 Ocugen Inc Earnings Call

Chester County gene therapy and biopharmaceutical company Ocugen has completed its previously announced reverse merger with Histogenics Corp., a publicly traded company based in Boston. Ocugen, which is developing new treatments for rare and underserved eye diseases, is now trading — at $2.50 per share Tuesday afternoon — on the Nasdaq Capital Market under the ticker symbol “OCGN.”  The executive team at Ocugen, led by Chairman and CEO Shankar Musunuri, is running the combined company which will be based in Malvern. Immediately prior to the merger, Ocugen (NASDAQ: OCGN) completed a $25 million private placement financing and Histogenics effected a reverse stock split of its common stock at a ratio of 1-for-60.

Histogenics Corporation (HSGX) (the “Company” or “Histogenics”) today announced that all proposals related to its proposed merger with Ocugen, Inc. (“Ocugen”) were approved by Histogenics’ stockholders at a special meeting held on September 26, 2019. As previously announced, the proposed merger will create a public company under which the stockholders of Ocugen will become majority holders of the combined company. The proposed merger remains subject to further customary closing conditions and regulatory approvals.